UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial

Journal for immunotherapy of cancer, 2023-10, Vol.11 (10), p.e007047

2023

Volltextzugriff (PDF)

Reactivation of Silenced, Virally Transduced Genes by Inhibitors of Histone Deacetylase

Proceedings of the National Academy of Sciences - PNAS, 1997-05, Vol.94 (11), p.5798-5803

1997

Volltextzugriff (PDF)

A Recombinant Human Hemoglobin with Anti-sickling Properties Greater than Fetal Hemoglobin

The Journal of biological chemistry, 2004-06, Vol.279 (26), p.27518-27524

2004

Volltextzugriff (PDF)

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

Journal for immunotherapy of cancer, 2022-08, Vol.10 (8), p.e004761

2022

Volltextzugriff (PDF)

Abstract LB033: Longitudinal ctDNA changes in patients with long-term response to palbociclib combination therapy for advanced breast cancer: A preliminary analysis from the real-world POLARIS study

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.LB033-LB033

2021

Volltextzugriff (PDF)

An open-label, multicenter, phase 2 study of the safety and efficacy of navtemadlin (KRT-232) in patients with TP53 wild-type relapsed/refractory small cell lung cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS8600-TPS8600

2022

Volltextzugriff (PDF)

Abstract P1-18-05: Early changes in circulating tumor DNA and its effect on clinical outcomes in patients with advanced breast cancer receiving the CDK4/6 inhibitor palbociclib: Genotyping results from POLARIS

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-18-05

2022

Volltextzugriff (PDF)

Abstract P1-18-25: Real-world quality of life (QoL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC) treated with palbociclib: A patient-reported outcome (PRO) analysis from POLARIS

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-18-25

2022

Volltextzugriff (PDF)

Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.22-22

2023

Volltextzugriff (PDF)

Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1004-1004

2021

Volltextzugriff (PDF)

CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5044-5044

2021

Volltextzugriff (PDF)

Abstract 443: Blood-based genotyping and clinical outcomes in patients with advanced breast cancer receiving the CDK4/6 inhibitor palbociclib in real-world settings: Results from POLARIS

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.443-443

2019

Volltextzugriff (PDF)

Symptom Burden in Extensive Disease Small Cell Lung Cancer (ED-SCLC): A prospective, observational study in U.S. community practices

Journal of clinical oncology, 2018-10, Vol.36 (30_suppl), p.196-196

2018

Volltextzugriff (PDF)

What is the benefit from second- and third-line (2L and 3L) therapy for extensive disease small cell lung cancer (ED-SCLC)? A prospective study of patterns, discontinuation, and survival in US community practices

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e20567-e20567

2018

Volltextzugriff (PDF)

Alemtuzumab in Relapsed or Refractory Chronic Lymphocytic Leukemia and Prolymphocytic Leukemia

Leukemia & lymphoma, 2002, Vol.43 (5), p.1007-1011

2002

Volltextzugriff (PDF)

Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9514-9514

2019

Volltextzugriff (PDF)

Abstract P5-02-22: Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving the Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib: Biomarker Results from POLARIS

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.P5-P5-02-22

2023

Volltextzugriff (PDF)

Recombinant Human Hemoglobins Designed for Gene Therapy of Sickle Cell Disease

Proceedings of the National Academy of Sciences - PNAS, 1994-10, Vol.91 (21), p.9852-9856

1994

Volltextzugriff (PDF)

Monoclonal antibody therapy in the treatment of non-Hodgkin lymphoma

JAMA : the journal of the American Medical Association, 2001-09, Vol.286 (10), p.1149

2001

Volltextzugriff (PDF)

Retroviral vector sequences inhibit human β-globin gene expression in transgenic mice

Nucleic acids research, 1994-10, Vol.22 (21), p.4477-4481

1994

Volltextzugriff (PDF)

[26] Preparation of recombinant hemoglobin in transgenic mice

Methods in Enzymology, 1994, Vol.231, p.403-434

1994

Volltextzugriff (PDF)

Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers

PLoS pathogens, 2013-10, Vol.9 (10), p.e1003691-e1003691

2013

Volltextzugriff (PDF)

Prednisolone or Pentoxifylline for Alcoholic Hepatitis

The New England journal of medicine, 2015-04, Vol.372 (17), p.1619-1628

2015

Volltextzugriff (PDF)

Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ART

PLoS pathogens, 2021-01, Vol.17 (1), p.e1009214

2021

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(77)
Mit Volltextzugriff
(67)

Publikationsform

Sprache

Englisch
(79)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial

Reactivation of Silenced, Virally Transduced Genes by Inhibitors of Histone Deacetylase

A Recombinant Human Hemoglobin with Anti-sickling Properties Greater than Fetal Hemoglobin

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

Abstract LB033: Longitudinal ctDNA changes in patients with long-term response to palbociclib combination therapy for advanced breast cancer: A preliminary analysis from the real-world POLARIS study

An open-label, multicenter, phase 2 study of the safety and efficacy of navtemadlin (KRT-232) in patients with TP53 wild-type relapsed/refractory small cell lung cancer

Abstract P1-18-05: Early changes in circulating tumor DNA and its effect on clinical outcomes in patients with advanced breast cancer receiving the CDK4/6 inhibitor palbociclib: Genotyping results from POLARIS

Abstract P1-18-25: Real-world quality of life (QoL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC) treated with palbociclib: A patient-reported outcome (PRO) analysis from POLARIS

Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial

Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC)

CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC)

Abstract 443: Blood-based genotyping and clinical outcomes in patients with advanced breast cancer receiving the CDK4/6 inhibitor palbociclib in real-world settings: Results from POLARIS

Symptom Burden in Extensive Disease Small Cell Lung Cancer (ED-SCLC): A prospective, observational study in U.S. community practices

What is the benefit from second- and third-line (2L and 3L) therapy for extensive disease small cell lung cancer (ED-SCLC)? A prospective study of patterns, discontinuation, and survival in US community practices

Alemtuzumab in Relapsed or Refractory Chronic Lymphocytic Leukemia and Prolymphocytic Leukemia

Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C

Abstract P5-02-22: Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving the Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib: Biomarker Results from POLARIS

Recombinant Human Hemoglobins Designed for Gene Therapy of Sickle Cell Disease

Monoclonal antibody therapy in the treatment of non-Hodgkin lymphoma

Retroviral vector sequences inhibit human β-globin gene expression in transgenic mice

[26] Preparation of recombinant hemoglobin in transgenic mice

HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality

Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers

Prednisolone or Pentoxifylline for Alcoholic Hepatitis

Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ART

Suchergebnisse filtern